Data gathered: February 1
AI Stock Analysis - Longeveron (LGVN)
Analysis generated December 9, 2024. Powered by Chat GPT.
Longeveron is an innovative biotechnology company focused on the development of cellular therapies for aging-related and life-threatening conditions. The company's proprietary stem cell therapies aim to treat diseases and disorders such as Alzheimer's, metabolic syndrome, and frailty in aging populations.
Stock Alerts - Longeveron (LGVN)
 |
Longeveron | January 31 Price is down by -5% in the last 24h. |
|
Longeveron | January 30 Price is up by 5.2% in the last 24h. |
|
Longeveron | January 29 Price is down by -5% in the last 24h. |
|
Longeveron | January 27 Price is down by -6% in the last 24h. |
Alternative Data for Longeveron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 517 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,374 | Sign up | Sign up | Sign up |
| Twitter Followers | 337 | Sign up | Sign up | Sign up |
| Twitter Mentions | 78 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 29 | Sign up | Sign up | Sign up |
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
| Price | $1.54 |
| Target Price | Sign up |
| Volume | 206,030 |
| Market Cap | $24M |
| Year Range | $0.82 - $4.55 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Longeveron to Present at Biotech Showcase 2025December 18 - GlobeNewswire |
|
Mesenchymal Stem Cells/Medicinal Signaling Cells (MSCs) Advances & Applications Report 2025: Comprehensive Analysis Reveals 125 Leading Competitors in MSC Research, Therapeutics and Market ExpansionJanuary 7 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 770,000 | 91,000 | 680,000 | -4.4M | -4.4M | -0.340 |
| Q2 '24 | 470,000 | 120,000 | 340,000 | -3.4M | -3.3M | -1.830 |
| Q1 '24 | 550,000 | 220,000 | 330,000 | -4.1M | -3.8M | -1.610 |
| Q4 '23 | 63,000 | 65,000 | -2,000 | -6M | -4.7M | -0.250 |
| Q3 '23 | 150,000 | 96,000 | 54,000 | -5.1M | -5.1M | -0.280 |
Insider Transactions View All
| Baluch Khoso filed to sell 23,750 shares at $2.1. December 4 '24 |
| Soffer Rock filed to buy 31,915 shares at $0.1. April 12 '24 |
| Hashad Mohamed Wa'el Ahmed filed to buy 10,638 shares at $0.1. April 12 '24 |
| Hare Joshua filed to buy 42,553 shares at $0.1. April 12 '24 |
| Soffer Rock filed to buy 106,383 shares at $0.1. April 12 '24 |
Similar companies
Read more about Longeveron (LGVN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Longeveron?
The Market Cap of Longeveron is $24M.
What is the current stock price of Longeveron?
Currently, the price of one share of Longeveron stock is $1.54.
How can I analyze the LGVN stock price chart for investment decisions?
The LGVN stock price chart above provides a comprehensive visual representation of Longeveron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Longeveron shares. Our platform offers an up-to-date LGVN stock price chart, along with technical data analysis and alternative data insights.
Does LGVN offer dividends to its shareholders?
As of our latest update, Longeveron (LGVN) does not offer dividends to its shareholders. Investors interested in Longeveron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Longeveron?
Some of the similar stocks of Longeveron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.